DLin-KC2-DMA|cas:1190197-97-7|西域试剂

DLin-KC2-DMA,98.0%

产品编号：Bellancom-112758| CAS NO：1190197-97-7| 分子式：C₄₃H₇₉NO₂| 分子量：642.09

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-112758	￥3500.00	杭州北京（现货）
Bellancom-112758	￥11000.00	杭州北京（现货）
Bellancom-112758	￥0.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

DLin-KC2-DMA

产品介绍

DLin-KC2-DMA 是一种可电离阳离子脂质 (pKa≈6)，对抗原呈递细胞 (APCs) 几乎无毒性。DLin-KC2-DMA 与纳米脂质颗粒(LNP) 结合后，可产生明显的 siRNA 介导的 GAPDH 基因沉默。DLin-KC2-DMA 可用于 siRNA 传递的研究。

生物活性

DLin-KC2-DMA is an ionisable cationic lipid (pKa≈6) that is virtually non-toxic to antigen presenting cells (APCs). DLin-KC2-DMA produces significant siRNA-mediated gene silencing of GAPDH, when binds to lipid nanoparticles (LNP). DLin-KC2-DMA can be used in siRNA delivery studies.

体外研究

DLin-KC2-DMA (1, 5 μg; 72 h) effectively produces a significant siRNA-mediated GAPDH gene silencing in both macrophages and dendritic cells.
DLin-KC2-DMA (24 h) exhibits high uptake into macrophages and dendritic cells.
DLin-KC2-DMA efficiently promotes release of encapsulated siRNA into the cytosol following uptake via the endocytotic pathway.
DLin-KC2-DMA displays almost no toxicity in primary APCs.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay

Cell Line:	Macrophages, dendritic cells
Concentration:	5 μg/mL (DLin-KC2-DMA contained-LNPs)
Incubation Time:	72 h
Result:	Displayed almost no toxicity.

Western Blot Analysis

Cell Line:	Macrophages, dendritic cells
Concentration:	1, 5 μg
Incubation Time:	72 h
Result:	Exhibited significant GAPDH silencing of more than 60% at 1 μg and of 80% at 5 μg in macrophages. Significantly reduced GAPDH protein and exhibited the silencing effects of 83% at 5 μg.

体内研究
(In Vivo)

DLin-KC2-DMA contained-LNP siRNA systems (5 mg/kg; i.v.; single) effectively silences target genes in APcs in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Naive C57BL/6 mice.
Dosage:	3 or 5 mg/kg (DLin-KC2-DMA contained-LNPs)
Administration:	Intravenous injection; single.
Result:	Significantly reduced GAPDH production in peritoneal cavity macrophages and dendritic cells and in the spleen-derived APCs when at 5 mg/kg.

体内研究

DLin-KC2-DMA contained-LNP siRNA systems (5 mg/kg; i.v.; single) effectively silences target genes in APcs in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Naive C57BL/6 mice.
Dosage:	3 or 5 mg/kg (DLin-KC2-DMA contained-LNPs)
Administration:	Intravenous injection; single.
Result:	Significantly reduced GAPDH production in peritoneal cavity macrophages and dendritic cells and in the spleen-derived APCs when at 5 mg/kg.

体内研究

DLin-KC2-DMA contained-LNP siRNA systems (5 mg/kg; i.v.; single) effectively silences target genes in APcs in vivo.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Naive C57BL/6 mice.
Dosage:	3 or 5 mg/kg (DLin-KC2-DMA contained-LNPs)
Administration:	Intravenous injection; single.
Result:	Significantly reduced GAPDH production in peritoneal cavity macrophages and dendritic cells and in the spleen-derived APCs when at 5 mg/kg.

性状

Liquid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (155.74 mM; Need ultrasonic)

Ethanol : 100 mg/mL (155.74 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.5574 mL	7.7871 mL	15.5741 mL
5 mM	0.3115 mL	1.5574 mL	3.1148 mL
10 mM	0.1557 mL	0.7787 mL	1.5574 mL

请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现用现配，即刻使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.89 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.89 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.89 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.89 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。